Overview


Prophylactic human vaccinations enhance the immune response and are meant to reduce the consequences of future pathogen infection in humans. Hepatitis B Virus (HBV) and Human Papilloma Virus (HPV) vaccines are being developed using novel vaccine development methods such as viral-like particles. CureVac AG, for example, earned a EUR 2 million Vaccination Prize from the European Commission for their unique RNActive vaccine technology. This RNActive vaccine technology enables the manufacturing of safe, effective, and cost-efficient vaccinations that are resistant to high temperatures as well as accidental freezing.

During the projected period, the prophylactic human vaccine market is likely to rise due to an increase in pipeline research and increased engagement of major companies in vaccine development. CureVac AG, for example, stated in October 2018 that it will begin a dosage escalation phase I clinical trial for CV7202 mRNA-based rabies vaccine. CV7202 is a preventive vaccination that contains the rabies virus glycoprotein RABV-G. This allows vaccinated individuals' own cells to manufacture RABV-G protein, triggering an immunological response. The investigation is expected to be completed. Furthermore, increased endeavours by various scientists to discover creative ways to combat infectious illnesses are likely to propel market expansion. In September 2018, VBI Vaccines Inc. announced the creation of three Scientific and Clinical Advisory Boards (SABs) comprised of prominent specialists in infectious disease and immuno-oncology research and vaccine development targeting hepatitis B, Cytomegalovirus (CMV), and Glioblastoma (GBM). Because of improved vaccine development, this partnership is projected to fuel market expansion. Significant vaccine development challenges, such as viral variety and a scarcity of animal models, are expected to stymie the expansion of the preventive human vaccination industry. According to Gastroenterology in October 2018, vaccine development demands a large investment from a variety of resources and is quite difficult. Designing human vaccination trials is difficult since the risks of developing an acute illness after inoculation are relatively high. As a result, anti-viral medication must be provided quickly, making illness management difficult.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Prophylactic Human Vaccines Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the Prophylactic Human Vaccines Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • GlaxoSmithKline Plc.
  • Merck and Co., Inc.
  • Pfizer, Inc.
  • Janssen Pharmaceuticals, Inc.
  • Altimmune, Inc.
  • Bharat Biotech Limited
  • Serum Institute of India, Pvt. Ltd
  • Sanofi Pasteur SA
  • Shanghai BravoBio Co., Ltd.
  • SK Chemicals Co., Ltd.

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Vaccine Technology

  • Live Attenuated vaccine
  • Inactivated Vaccines
  • Toxoid Vaccines
  • Polysaccharide Vaccines
  • Conjugate Vaccines
  • Recombinant Vaccines

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Prophylactic Human Vaccines Market By Vaccine Technology and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Prophylactic Human Vaccines Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Prophylactic Human Vaccines Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Prophylactic Human Vaccines Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Prophylactic Human Vaccines Market, By Vaccine Technology Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Live Attenuated vaccine
        2. Inactivated Vaccines
        3. Toxoid Vaccines
        4. Polysaccharide Vaccines
        5. Conjugate Vaccines
        6. Recombinant Vaccines

  • 8.   North America Prophylactic Human Vaccines Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 9.   Latin America Prophylactic Human Vaccines Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 10.   Europe Prophylactic Human Vaccines Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.7. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 11.   Asia Pacific Prophylactic Human Vaccines Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 12.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 13.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 14.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. GlaxoSmithKline Plc.
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Merck and Co., Inc.
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Pfizer, Inc.
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Janssen Pharmaceuticals, Inc.
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Altimmune, Inc.
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Bharat Biotech Limited
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Serum Institute of India, Pvt. Ltd
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Sanofi Pasteur SA
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Shanghai BravoBio Co., Ltd.
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. SK Chemicals Co., Ltd.
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 15.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 16.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients